S&P 500   3,855.47
DOW   31,170.54
QQQ   324.22
S&P 500   3,855.47
DOW   31,170.54
QQQ   324.22
S&P 500   3,855.47
DOW   31,170.54
QQQ   324.22
S&P 500   3,855.47
DOW   31,170.54
QQQ   324.22
Log in
ASX:CP1

CannPal Animal Therapeutics Limited (CP1.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.09
MA: A$0.09
A$0.09
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.

MarketRank

Overall MarketRank

0.44 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 6108 3622
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$704,421.00
Book ValueA$0.02 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive CP1 News and Ratings via Email

Sign-up to receive the latest news and ratings for CP1 and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CannPal Animal Therapeutics Limited (CP1.AX) (ASX:CP1) Frequently Asked Questions

What stocks does MarketBeat like better than CannPal Animal Therapeutics Limited (CP1.AX)?

Wall Street analysts have given CannPal Animal Therapeutics Limited (CP1.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CannPal Animal Therapeutics Limited (CP1.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of CannPal Animal Therapeutics Limited (CP1.AX)'s key competitors?

Who are CannPal Animal Therapeutics Limited (CP1.AX)'s key executives?

CannPal Animal Therapeutics Limited (CP1.AX)'s management team includes the following people:
  • Mr. Layton Patrick Mills, Founder, MD & Director
  • Dr. Margaret Curtis, Head of Clinical Devel. and R&D
  • Mr. Baden Maxwell Bowen, CFO & Company Sec.
  • Dr. Rayson Tan, Chief Scientific Officer & Member of Advisory Board

What is CannPal Animal Therapeutics Limited (CP1.AX)'s stock symbol?

CannPal Animal Therapeutics Limited (CP1.AX) trades on the ASX under the ticker symbol "CP1."

How big of a company is CannPal Animal Therapeutics Limited (CP1.AX)?

CannPal Animal Therapeutics Limited (CP1.AX) has a market capitalization of $0.00 and generates $704,421.00 in revenue each year.

What is CannPal Animal Therapeutics Limited (CP1.AX)'s official website?

The official website for CannPal Animal Therapeutics Limited (CP1.AX) is www.cannpal.com.

How can I contact CannPal Animal Therapeutics Limited (CP1.AX)?

The company can be reached via phone at 61 2 6108 3622.

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.